DRUG FOOD INTERACTION POTENTIAL OF CLARITHROMYCIN, A NEW MACROLIDE ANTIMICROBIAL

被引:38
作者
CHU, SY
PARK, Y
LOCKE, C
WILSON, DS
CAVANAUGH, JC
机构
[1] ABBOTT LABS,BIOAVAILABIL UNIV,ABBOTT PK,IL
[2] ABBOTT LABS,DEPT BIOSTAT,ABBOTT PK,IL
关键词
D O I
10.1002/j.1552-4604.1992.tb03784.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To evaluate the effect of food on bioavailability, clarithromycin and 14-hydroxyclarithromycin (active metabolite) pharmacokinetics were assessed in 26 healthy adult volunteers after ingestion of a single oral 500-mg dose of clarithromycin in a fasting state (2 hours before breakfast after an overnight fast) and a nonfasting state (0.5 hours after the start of breakfast). Clarithromycin and 14-hydroxy metabolite plasma concentrations were measured using a high-performance liquid chromatographic technique. Food intake immediately before dosing increased the extent of absorption from the 500-mg tablet formulation by approximately 25%. The mean increase in metabolite area under the plasma concentration-time curve was approximately 9%. These results suggest that clarithromycin can be taken without regard to timing in relation to meals.
引用
收藏
页码:32 / 36
页数:5
相关论文
共 28 条
[1]  
Akaike H., 1976, MATH SCI, V14, P5
[2]   SIMULTANEOUS DETERMINATION OF CLARITHROMYCIN AND 14(R)-HYDROXYCLARITHROMYCIN IN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
CHU, SY ;
SENNELLO, LT ;
SONDERS, RC .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1991, 571 (1-2) :199-208
[3]  
CHUN AHC, 1977, INFECTION, V5, pS14
[4]   BIOAVAILABILITY OF ERYTHROMYCIN ETHYLSUCCINATE IN PEDIATRIC-PATIENTS [J].
COYNE, TC ;
SHUM, S ;
CHUN, AHC ;
JEANSONNE, L ;
SHIRKEY, HC .
JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 18 (04) :194-202
[5]  
DISANT OR, 1981, ANTIMICROB AGENTS CH, V20, P190
[6]   COMPARATIVE BIOAVAILABILITY EVALUATION OF ERYTHROMYCIN BASE AND ITS SALTS AND ESTERS .1. ERYTHROMYCIN ESTOLATE CAPSULES VERSUS ENTERIC-COATED ERYTHROMYCIN BASE TABLETS [J].
DISANTO, AR ;
TSERNG, KY ;
CHODOS, DJ ;
DESANTE, KA ;
ALBERT, KS ;
WAGNER, JG .
JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 20 (07) :437-443
[7]   CLINICAL EFFICACY AND TOLERANCE OF 2 NEW MACROLIDES, CLARITHROMYCIN AND JOSAMYCIN, IN THE TREATMENT OF PATIENTS WITH ACUTE EXACERBATIONS OF CHRONIC-BRONCHITIS [J].
FRASCHINI, F .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1990, 18 (02) :171-176
[8]  
FUKAYA K, 1981, ACTA TOXICOL THER, V2, P45
[9]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[10]   COMPARATIVE ANTIMYCOBACTERIAL ACTIVITIES OF DIFLOXACIN, TEMAFLOXACIN, ENOXACIN, PEFLOXACIN, REFERENCE FLUOROQUINOLONES, AND A NEW MACROLIDE, CLARITHROMYCIN [J].
GORZYNSKI, EA ;
GUTMAN, SI ;
ALLEN, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :591-592